Skip to main content
. Author manuscript; available in PMC: 2015 Jun 22.
Published in final edited form as: Cancer. 2010 May 15;116(10):2360–2365. doi: 10.1002/cncr.24958

Figure 1.

Figure 1

Time to treatment failure is shown comparing continuous intravenous infusion (civ) alemtuzumab/subcutaneous (sc) alemtuzumab with 2 historical control groups: 1) patients (Pts) treated with single-agent alemtuzumab and 2) those treated with intravenous alemtuzumab plus rituximab (A/R).